Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) just unveiled an update.
BeOne Medicines Ltd. will release its fourth-quarter and full-year 2025 financial results, prepared under U.S. GAAP and SEC rules, on February 26, 2026, after Hong Kong trading hours, with the board set to review and approve the figures the same day. Management will host a live webcasted conference call that morning U.S. Eastern Time, with an archived version available on the company’s investor website.
The company also plans to publish its audited 2025 results in line with Hong Kong Stock Exchange listing rules by March 31, 2026, including a reconciliation from U.S. GAAP to IFRS and any additional required disclosures. The timetable underscores BeOne’s efforts to maintain transparency for both U.S.- and Hong Kong-focused investors and to align its reporting across multiple regulatory regimes.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange. The company reports its financial results under U.S. GAAP and also prepares reconciliations to International Financial Reporting Standards to meet Hong Kong listing requirements, reflecting a cross-border regulatory and investor focus.
Average Trading Volume: 3,815,238
Technical Sentiment Signal: Buy
Current Market Cap: HK$328.4B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.